tc-6987
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2011 (NCT01293669)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
CHRNA7 agonist
Open channel stabilizer.
Chemistry & pharmacology
Loading structure…
SMILES
O=C(N[C@@H]1C2CCN(CC2)[C@H]1Cc1cccnc1)c1cc(F)cc(F)c1- Mol. weight
- 357.4 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314402 ↗
- ChEMBLCHEMBL3545410 ↗
Also known as
- tc-6987
- tc-6987
- tc-6987
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01296087 | Phase 2 | Feb 1, 2011 | Targacept, Toledo Center for Clinical Research |
| NCT01293669 | Phase 2 | Jan 1, 2011 | Eastern Virginia Medical School, Targacept |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Targacept | For profit | 2 | 2 | 1 | 2011 |
| Eastern Virginia Medical School | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Toledo Center for Clinical Research | Academic/Hospital | 1 | 0 | 1 | 2011 |
3 organizations
Page 1 / 1